Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
Lung cancer is the most frequently diagnosed cancer and a leading cause of cancer mortality worldwide, with adenocarcinoma being the most common histological subtype. Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small molecules that tar...
Main Authors: | Niki Karachaliou, Rafael Rosell |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2014-09-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/650 |
Similar Items
-
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
by: Yue Pan, et al.
Published: (2021-10-01) -
An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance
by: Adela Patcas, et al.
Published: (2021-05-01) -
Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer
by: Xin WANG, et al.
Published: (2018-09-01) -
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-07-01) -
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma
by: Kai Yin, et al.
Published: (2020-02-01)